Not Signed In - Drug Shown To Be Clinically Active Against Multiple Target Mutations In Two Types Of Leukemia ...
Thu, 21 Dec 2006 04:00 AM EST
... Researchers at the University of Texas M. D. Anderson Cancer Center report that MK-0457 (VX-680), a novel multi-kinase inhibitor, is clinically active against multiple target mutations in two types of leukemia and myeloproliferative disorders, and produces few side effects for patients. ...
Related Topics
- Leukemia
- Myeloma, Multiple
- Multiple Myeloma
- Myeloma
- Childhood Leukemia
- Leukemia, Childhood
- Multiple Chemical Sensitivity
- Chronic Lymphocytic Leukemia
- Leukemia, Chronic Lymphocytic
- Drug Safety
- Prescription Drugs
- Drug Side Effects
- Twins, Triplets, Multiple Births
- Multiple System Atrophy
- Drug Abuse
- Drug Information
- Prescription Drug Abuse
- Prescription Drugs Abuse
- Thalidomide
- Recessive multiple epiphyseal dysplasia
email this page
print this page
bookmark this page
feedback on this page
